These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20812364)

  • 1. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Rowe IA
    Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

  • 3. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
    Kim R; Menon N; Aucejo F
    Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma: the search for innovative adjuvant therapies.
    Yen Y; Zhou W
    Oncology (Williston Park); 2009 Dec; 23(14):1291, 1294. PubMed ID: 20120843
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
    Zhu AX
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
    Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
    Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
    Vitale A; Lombardi G; Ramirez Morales R; Cillo U
    Dig Liver Dis; 2012 May; 44(5):361-2. PubMed ID: 22424640
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib for liver cancer: the horizon broadens.
    Johnson P; Billingham L
    Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 12. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib for HCC: a pragmatic perspective.
    Razumilava N; Gores GJ
    Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
    [No Abstract]   [Full Text] [Related]  

  • 14. Sorafenib, a systemic therapy for hepatocellular carcinoma.
    Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
    Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
    Matsuda Y; Ichida T; Fukumoto M
    Med Mol Morphol; 2011 Sep; 44(3):117-24. PubMed ID: 21922382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
    Pazo Cid RA; Lao J; Lanzuela M
    JAMA; 2011 Feb; 305(8):781; author reply 781. PubMed ID: 21343576
    [No Abstract]   [Full Text] [Related]  

  • 17. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW
    Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX; Clark JW
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract]   [Full Text] [Related]  

  • 19. Health-related quality of life and sorafenib.
    Spinzi G; Terreni N
    Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
    [No Abstract]   [Full Text] [Related]  

  • 20. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
    Abou-Alfa GK
    Oncologist; 2009 Jan; 14(1):92-4. PubMed ID: 19144679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.